TY - JOUR
T1 - Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation
T2 - Results From the ORBIT-AF Registry
AU - Pandey, Ambarish
AU - Gersh, Bernard J.
AU - McGuire, Darren K
AU - Shrader, Peter
AU - Thomas, Laine
AU - Kowey, Peter R.
AU - Mahaffey, Kenneth W.
AU - Hylek, Elaine
AU - Sun, Shining
AU - Burton, Paul
AU - Piccini, Jonathan
AU - Peterson, Eric
AU - Fonarow, Gregg C.
N1 - Funding Information:
The ORBIT-AF registry is sponsored by Janssen Scientific Affairs, LLC, Raritan, New Jersey. Dr. Fonarow has received research support from Agency for Healthcare Research and Quality and consultancy fees from Janssen and Medtronic. Dr. Gersh is on the data safety and monitoring board for Baxter Healthcare Corporation, Cardiovascular Research Foundation, St. Jude Medical, Boston Scientific; is a member of steering committee for Medtronic; and is a member of the executive committee for Ortho-McNeil Janssen Scientific Affairs. Dr. McGuire has received honoraria for trial leadership and consultation with GlaxoSmithKline, The Medicines Company, Takeda Pharmaceuticals, Novo Nordisk, Orexigen, Cubist, Janssen, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Merck, Regeneron, Lexicon, and Eisai. Dr. Kowey has served as a consultant to or on the advisory board of Johnson & Johnson, Daiichi Sankyo, Sanofi, Boehringer Ingelheim, Merck, Bristol-Myers Squibb, and Portola. Dr. Mahaffey has served as a consultant for the American College of Cardiology, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cubist, Daiichi, Eli Lilly, Elsevier, Forest, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Mt. Sinai, Myokardia, Omthera, Portola, Purdue Pharma, Spring Publishing, St. Jude Medical, Tenax, The Medicines Company, and WebMD. Dr. Peterson has received research grants from the American Heart Association, the American College of Cardiology, Janssen Pharmaceutical Products, Eli Lilly & Co, and the Society of Thoracic Surgeons; has served as a consultant to or on the advisory board of Merck & Co, Boehringer Ingelheim, Genentech, Sanofi-Aventis, and Janssen Pharmaceutical Products. Dr. Piccini has received research grants from Johnson & Johnson/Janssen Pharmaceuticals and Boston Scientific Corp.; received other research support from Johnson & Johnson/Janssen Pharmaceuticals; and received consultant/advisory board fees from Forest Laboratories, Inc., Medtronic Inc., and Johnson & Johnson/Janssen Pharmaceuticals. Dr. Hylek has received honoraria for consultancy from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, and Medtronic & Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2016 American College of Cardiology Foundation
PY - 2016
Y1 - 2016
N2 - Objectives This study sought to determine the association between body mass index (BMI) and clinical outcomes among patients with prevalent atrial fibrillation (AF). Background Higher BMI is an independent risk factor for incident AF. However, its impact on management strategies and clinical outcomes among patients with prevalent AF is unclear. Methods Patients with AF enrolled in the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry from June 2010 through August 2011 were stratified into BMI-based categories as normal weight, overweight, class I obese, class II obese, and class III obese. Unadjusted and adjusted Cox frailty models were constructed to assess the association of BMI with clinical outcomes over a 2-year follow-up. Results We evaluated 9,606 patients with AF (42% women; 78% overweight/obese) from 174 ORBIT participating practices in the United States. Higher BMI patients were younger and had a greater prevalence of diabetes, hypertension, and obstructive sleep apnea (OSA). Use of anticoagulation and rhythm control strategies was significantly greater among higher BMI patients. Rates for all-cause mortality and thromboembolic events decreased in a near linear fashion across increasing BMI categories (p < 0.001). After multivariable adjustment, higher BMI was associated with lower risk for all-cause mortality with lowest risk among class I obese patients (hazard ratio [HR]: 0.65; 95% CI: 0.54 to 0.78); reference: normal weight). For every 5-kg/m2 increase in BMI, the odds of risk-adjusted mortality were 7% lower. In contrast, BMI was not associated with adjusted risk for thromboembolic events and AF progression. Conclusions Although AF patients with higher BMI were significantly younger, higher BMI in AF patients was associated with similar or better clinical outcomes.
AB - Objectives This study sought to determine the association between body mass index (BMI) and clinical outcomes among patients with prevalent atrial fibrillation (AF). Background Higher BMI is an independent risk factor for incident AF. However, its impact on management strategies and clinical outcomes among patients with prevalent AF is unclear. Methods Patients with AF enrolled in the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry from June 2010 through August 2011 were stratified into BMI-based categories as normal weight, overweight, class I obese, class II obese, and class III obese. Unadjusted and adjusted Cox frailty models were constructed to assess the association of BMI with clinical outcomes over a 2-year follow-up. Results We evaluated 9,606 patients with AF (42% women; 78% overweight/obese) from 174 ORBIT participating practices in the United States. Higher BMI patients were younger and had a greater prevalence of diabetes, hypertension, and obstructive sleep apnea (OSA). Use of anticoagulation and rhythm control strategies was significantly greater among higher BMI patients. Rates for all-cause mortality and thromboembolic events decreased in a near linear fashion across increasing BMI categories (p < 0.001). After multivariable adjustment, higher BMI was associated with lower risk for all-cause mortality with lowest risk among class I obese patients (hazard ratio [HR]: 0.65; 95% CI: 0.54 to 0.78); reference: normal weight). For every 5-kg/m2 increase in BMI, the odds of risk-adjusted mortality were 7% lower. In contrast, BMI was not associated with adjusted risk for thromboembolic events and AF progression. Conclusions Although AF patients with higher BMI were significantly younger, higher BMI in AF patients was associated with similar or better clinical outcomes.
KW - atrial fibrillation
KW - body mass index
KW - mortality
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=84979205219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979205219&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2015.12.001
DO - 10.1016/j.jacep.2015.12.001
M3 - Article
C2 - 29766895
AN - SCOPUS:84979205219
SN - 2405-500X
VL - 2
SP - 355
EP - 363
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 3
ER -